Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression.

Wilson A, Urquhart BL, Ponich T, Chande N, Gregor JC, Beaton M, Kim RB.

Mol Pharm. 2019 Aug 19. doi: 10.1021/acs.molpharmaceut.9b00459. [Epub ahead of print]

PMID:
31393129
2.

The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.

Kucey AS, Velenosi TJ, Tonial NC, Tieu A, RaoPeters AAE, Urquhart BL.

Pharmacol Res Perspect. 2019 Apr 26;7(3):e00475. doi: 10.1002/prp2.475. eCollection 2019 Jun.

3.

Untargeted metabolomics reveals N, N, N-trimethyl-L-alanyl-L-proline betaine (TMAP) as a novel biomarker of kidney function.

Velenosi TJ, Thomson BKA, Tonial NC, RaoPeters AAE, Mio MA, Lajoie GA, Garg AX, House AA, Urquhart BL.

Sci Rep. 2019 May 2;9(1):6831. doi: 10.1038/s41598-019-42992-3.

4.

Sapropterin Treatment Prevents Congenital Heart Defects Induced by Pregestational Diabetes Mellitus in Mice.

Engineer A, Saiyin T, Lu X, Kucey AS, Urquhart BL, Drysdale TA, Norozi K, Feng Q.

J Am Heart Assoc. 2018 Nov 6;7(21):e009624. doi: 10.1161/JAHA.118.009624.

5.

Moderate Renal Impairment and Toxic Metabolites Produced by the Intestinal Microbiome: Dietary Implications.

Pignanelli M, Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Urquhart BL, Ruetz KN, Velenosi TJ, Spence JD.

J Ren Nutr. 2019 Jan;29(1):55-64. doi: 10.1053/j.jrn.2018.05.007. Epub 2018 Aug 9.

PMID:
30100156
6.

Mediterranean Diet Score: Associations with Metabolic Products of the Intestinal Microbiome, Carotid Plaque Burden, and Renal Function.

Pignanelli M, Just C, Bogiatzi C, Dinculescu V, Gloor GB, Allen-Vercoe E, Reid G, Urquhart BL, Ruetz KN, Velenosi TJ, Spence JD.

Nutrients. 2018 Jun 16;10(6). pii: E779. doi: 10.3390/nu10060779.

7.

Metabolic products of the intestinal microbiome and extremes of atherosclerosis.

Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Wong RG, Urquhart BL, Dinculescu V, Ruetz KN, Velenosi TJ, Pignanelli M, Spence JD.

Atherosclerosis. 2018 Jun;273:91-97. doi: 10.1016/j.atherosclerosis.2018.04.015. Epub 2018 Apr 17.

PMID:
29702430
8.

β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL.

Clin J Am Soc Nephrol. 2018 Apr 6;13(4):604-611. doi: 10.2215/CJN.07470717. Epub 2018 Mar 8.

9.

Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically.

Dresser GK, Urquhart BL, Proniuk J, Tieu A, Freeman DJ, Arnold JM, Bailey DG.

Pharmacol Res Perspect. 2017 Oct;5(5). doi: 10.1002/prp2.346.

10.

Endogenous Glucocorticoid Response to Single-Dose Dexamethasone for Croup in Children: A Pharmacodynamic Study.

Gill N, Sirizzotti N, Johnson D, Joubert G, Kucey AS, Tieu A, Urquhart BL, Columbus M, Lim R, Rieder M, Mehrotra S, Hartjes ED, Poonai N.

Pediatr Emerg Care. 2017 Apr 11. doi: 10.1097/PEC.0000000000001142. [Epub ahead of print]

PMID:
28398936
11.

Coffee-Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study With Felodipine.

Bailey DG, Dresser GK, Urquhart BL, Freeman DJ, Arnold JM.

Am J Hypertens. 2016 Dec 1;29(12):1386-1393. doi: 10.1093/ajh/hpw081.

PMID:
27481881
12.

Metabolomic Response of Skeletal Muscle to Aerobic Exercise Training in Insulin Resistant Type 1 Diabetic Rats.

Dotzert MS, Murray MR, McDonald MW, Olver TD, Velenosi TJ, Hennop A, Noble EG, Urquhart BL, Melling CW.

Sci Rep. 2016 May 20;6:26379. doi: 10.1038/srep26379.

13.

Clearance of cardiovascular medications during hemodialysis.

Tieu A, Leither M, Urquhart BL, Weir MA.

Curr Opin Nephrol Hypertens. 2016 May;25(3):257-67. doi: 10.1097/MNH.0000000000000216. Review.

PMID:
27023840
14.

Drug Disposition Issues in CKD: Implications for Drug Discovery and Regulatory Approval.

Tieu A, House AA, Urquhart BL.

Adv Chronic Kidney Dis. 2016 Mar;23(2):63-6. doi: 10.1053/j.ackd.2016.01.013. Review.

PMID:
26979144
15.

Untargeted plasma and tissue metabolomics in rats with chronic kidney disease given AST-120.

Velenosi TJ, Hennop A, Feere DA, Tieu A, Kucey AS, Kyriacou P, McCuaig LE, Nevison SE, Kerr MA, Urquhart BL.

Sci Rep. 2016 Mar 2;6:22526. doi: 10.1038/srep22526.

16.

Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine.

Spence JD, Urquhart BL, Bang H.

Nephrol Dial Transplant. 2016 Jun;31(6):937-44. doi: 10.1093/ndt/gfv380. Epub 2015 Nov 14.

17.

Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Dorman SN, Baranova K, Knoll JH, Urquhart BL, Mariani G, Carcangiu ML, Rogan PK.

Mol Oncol. 2016 Jan;10(1):85-100. doi: 10.1016/j.molonc.2015.07.006. Epub 2015 Aug 22.

18.

Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease.

Alshogran OY, Urquhart BL, Nolin TD.

Drug Metab Lett. 2015;9(2):111-8.

PMID:
26282591
19.

Folic Acid for Stroke Prevention: Time to Revisit Vitamin Therapy in Patients With Kidney Disease?

House AA, Urquhart BL.

Am J Kidney Dis. 2015 Dec;66(6):942-4. doi: 10.1053/j.ajkd.2015.06.009. Epub 2015 Jul 14. No abstract available.

PMID:
26187470
20.

Dried blood spots for therapeutic drug monitoring of tacrolimus and sirolimus in pediatric patients.

Urquhart BL, Knauer MJ.

Pediatr Transplant. 2015 Feb;19(1):3-4. doi: 10.1111/petr.12394. No abstract available.

PMID:
25546506
21.

Enzymatic and non-enzymatic mechanisms of dimesna metabolism.

Cutler MJ, Velenosi TJ, Bodalia A, House AA, Urquhart BL, Freeman DJ.

Amino Acids. 2015 Mar;47(3):511-23. doi: 10.1007/s00726-014-1882-0. Epub 2014 Dec 10.

PMID:
25488427
22.

Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.

Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL.

Am J Kidney Dis. 2015 Apr;65(4):574-82. doi: 10.1053/j.ajkd.2014.09.015. Epub 2014 Nov 21.

PMID:
25453994
23.

Breast cancer resistance protein substrate and inhibition evaluation: why, when, and how?

Ware JA, Urquhart BL, Sugiyama Y, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2014 Dec;42(12):1979-80. doi: 10.1124/dmd.114.060970. No abstract available.

PMID:
25362071
24.

Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease.

Feere DA, Velenosi TJ, Urquhart BL.

Br J Pharmacol. 2015 Jan;172(1):201-13. doi: 10.1111/bph.12932. Epub 2014 Nov 24.

25.

Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease.

Velenosi TJ, Feere DA, Sohi G, Hardy DB, Urquhart BL.

FASEB J. 2014 Dec;28(12):5388-97. doi: 10.1096/fj.14-258780. Epub 2014 Sep 10.

PMID:
25208844
26.

Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.

Velenosi TJ, Urquhart BL.

Expert Opin Drug Metab Toxicol. 2014 Aug;10(8):1131-43. doi: 10.1517/17425255.2014.931371. Epub 2014 Jun 24. Review.

PMID:
24961255
27.

CD73-TNAP crosstalk regulates the hypertrophic response and cardiomyocyte calcification due to α1 adrenoceptor activation.

Gan XT, Taniai S, Zhao G, Huang CX, Velenosi TJ, Xue J, Urquhart BL, Karmazyn M.

Mol Cell Biochem. 2014 Sep;394(1-2):237-46. doi: 10.1007/s11010-014-2100-9. Epub 2014 Jun 4.

PMID:
24894822
28.

N-Acetylcysteine prevents congenital heart defects induced by pregestational diabetes.

Moazzen H, Lu X, Ma NL, Velenosi TJ, Urquhart BL, Wisse LJ, Gittenberger-de Groot AC, Feng Q.

Cardiovasc Diabetol. 2014 Feb 18;13:46. doi: 10.1186/1475-2840-13-46.

29.

Design it yourself (DIY): in-house instructional design for online pharmacology.

Loftus J, Stavraky T, Urquhart BL.

Adv Health Sci Educ Theory Pract. 2014 Dec;19(5):645-59. doi: 10.1007/s10459-013-9492-2. Epub 2014 Jan 24.

PMID:
24458728
30.

Protein restoration in low-birth-weight rat offspring derived from maternal low-protein diet leads to elevated hepatic CYP3A and CYP2C11 activity in adulthood.

Sohi G, Barry EJ, Velenosi TJ, Urquhart BL, Hardy DB.

Drug Metab Dispos. 2014 Feb;42(2):221-8. doi: 10.1124/dmd.113.053538. Epub 2013 Nov 8.

PMID:
24212381
31.

Frequent nocturnal hemodialysis associates with improvement of prolonged QTc intervals.

Thomson BK, Momciu B, Huang SH, Chan CT, Urquhart BL, Skanes AC, Krahn AD, Klein GJ, Lindsay RM.

Nephron Clin Pract. 2013;123(1-2):74-82. doi: 10.1159/000351382. Epub 2013 Jul 11.

PMID:
23860412
32.

Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease.

Velenosi TJ, Fu AY, Luo S, Wang H, Urquhart BL.

Drug Metab Dispos. 2012 Aug;40(8):1508-14. doi: 10.1124/dmd.112.045245. Epub 2012 May 9.

PMID:
22573661
33.

Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.

Thirumaran RK, Lamba JK, Kim RB, Urquhart BL, Gregor JC, Chande N, Fan Y, Qi A, Cheng C, Thummel KE, Hall SD, Schuetz EG.

Biochem Pharmacol. 2012 Jul 1;84(1):104-12. doi: 10.1016/j.bcp.2012.03.017. Epub 2012 Mar 30.

34.

Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.

DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, Kim RB.

J Clin Pharmacol. 2012 Nov;52(11):1689-97. doi: 10.1177/0091270011422815. Epub 2011 Dec 13.

PMID:
22167570
35.

Functional characterization of genetic variants in the apical sodium-dependent bile acid transporter (ASBT; SLC10A2).

Ho RH, Leake BF, Urquhart BL, Gregor JC, Dawson PA, Kim RB.

J Gastroenterol Hepatol. 2011 Dec;26(12):1740-8. doi: 10.1111/j.1440-1746.2011.06805.x.

36.

In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.

Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ.

J Clin Pharmacol. 2012 Apr;52(4):530-42. doi: 10.1177/0091270011400414. Epub 2011 Apr 19.

PMID:
21505084
37.

Human skeletal muscle drug transporters determine local exposure and toxicity of statins.

Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG.

Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25.

PMID:
19940267
38.

The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs.

Urquhart BL, Gregor JC, Chande N, Knauer MJ, Tirona RG, Kim RB.

Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G248-54. doi: 10.1152/ajpgi.00224.2009. Epub 2009 Sep 17.

39.

Blood-brain barrier transporters and response to CNS-active drugs.

Urquhart BL, Kim RB.

Eur J Clin Pharmacol. 2009 Nov;65(11):1063-70. doi: 10.1007/s00228-009-0714-8. Review.

PMID:
19727692
40.

Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients.

Cutler MJ, Urquhart BL, Freeman DJ, Spence JD, House AA.

Blood Purif. 2009;27(3):306-10. doi: 10.1159/000207197. Epub 2009 Mar 9.

PMID:
19270449
41.

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.

Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB.

Pharmacogenet Genomics. 2008 May;18(5):439-48. doi: 10.1097/FPC.0b013e3282f974dc.

42.

Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.

Urquhart BL, Freeman DJ, Cutler MJ, Mainra R, Spence JD, House AA.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1041-7. doi: 10.2215/CJN.04771107. Epub 2008 Mar 12.

43.

Assessing plasma total homocysteine in patients with end-stage renal disease.

Urquhart BL, House AA.

Perit Dial Int. 2007 Sep-Oct;27(5):476-88. Review.

PMID:
17704433
44.

Mesna as a nonvitamin intervention to lower plasma total homocysteine concentration: implications for assessment of the homocysteine theory of atherosclerosis.

Urquhart BL, Freeman DJ, Spence JD, House AA.

J Clin Pharmacol. 2007 Aug;47(8):991-7. Epub 2007 Jul 5.

PMID:
17615252
45.
46.

The effect of mesna on plasma total homocysteine concentration in hemodialysis patients.

Urquhart BL, Freeman DJ, Spence JD, House AA.

Am J Kidney Dis. 2007 Jan;49(1):109-17.

PMID:
17185151
47.

Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.

Zheng X, Koropatnick J, Li M, Zhang X, Ling F, Ren X, Hao X, Sun H, Vladau C, Franek JA, Feng B, Urquhart BL, Zhong R, Freeman DJ, Garcia B, Min WP.

J Immunol. 2006 Oct 15;177(8):5639-46.

48.

Thiol exchange: an in vitro assay that predicts the efficacy of novel homocysteine lowering therapies.

Urquhart BL, House AA, Cutler MJ, Spence JD, Freeman DJ.

J Pharm Sci. 2006 Aug;95(8):1742-50.

PMID:
16795014
49.

Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.

House AA, Eliasziw M, Urquhart BL, Freeman DJ, Spence JD.

Am J Kidney Dis. 2004 Oct;44(4):689-94.

PMID:
15384020
50.

Pulmonary complications in anterior-posterior thoracic lumbar fusions.

Jules-Elysee K, Urban MK, Urquhart BL, Susman MH, Brown AC, Kelsey WT.

Spine J. 2004 May-Jun;4(3):312-6.

PMID:
15125855

Supplemental Content

Loading ...
Support Center